Trusted Resource for Clinical Trials, Protocols & Progress
Off-Label Use Monitoring in Phase 4 Clinical Trials Tracking and Managing Off-Label Drug Use Through Phase 4 Post-Marketing Surveillance Introduction Once a drug is on the market, physicians may begin using it for conditions beyond its approved label—a practice known as off-label use. While common and sometimes beneficial, off-label use can introduce safety risks that…
Read More “Off-Label Use Monitoring in Phase 4 Clinical Trials” »
Patient Recruitment Forecasting Models for Large-Scale Phase 3 Studies: Tools, Strategies, and Risk Control How to Forecast Patient Recruitment for Global Phase 3 Clinical Trials Why Patient Recruitment Forecasting Matters in Phase 3 Trials Recruiting eligible participants is one of the most critical—and challenging—components of any Phase 3 clinical trial. Delays in recruitment can derail…
Use of Patient Registries in Phase 4 Research How Patient Registries Support Safety and Outcomes Research in Phase 4 Clinical Trials Introduction Patient registries are organized systems that collect uniform data on a defined population over time. In Phase 4 clinical trials, registries offer unparalleled opportunities to track drug safety, effectiveness, adherence, and real-world outcomes…
Global Site Feasibility and Selection Strategies for Phase 3 Trials: Ensuring Optimal Trial Execution How to Select the Right Sites Globally for Phase 3 Clinical Trials Why Site Selection Is Critical in Phase 3 Trials Phase 3 clinical trials are large-scale, multi-country studies requiring rapid enrollment, consistent data quality, and regulatory compliance. One of the…
Using Real-World Evidence (RWE) to Complement Phase 3 Data: Enhancing Clinical Trial Outcomes and Regulatory Value How Real-World Evidence Can Strengthen Phase 3 Clinical Trial Programs Why Real-World Evidence Matters in the Phase 3 Context Phase 3 clinical trials provide controlled and statistically powered evidence on a drug’s safety and efficacy. However, they are conducted…
Real-World Evidence (RWE) Generation from Phase 4 Trials Generating High-Impact Real-World Evidence from Phase 4 Clinical Trials Introduction Real-World Evidence (RWE) has emerged as a powerful supplement to traditional clinical trial data, especially in Phase 4 trials. Generated from everyday patient experiences and routine care, RWE provides actionable insights that inform healthcare decisions, payer coverage,…
Read More “Real-World Evidence (RWE) Generation from Phase 4 Trials” »
Using External and Historical Controls in Phase 2 Trials Leveraging External and Historical Controls in Phase 2 Clinical Trial Designs Introduction In certain therapeutic areas—especially rare diseases, oncology, and life-threatening conditions—randomized controlled trials may be impractical or ethically challenging in Phase 2. In such cases, researchers may use external or historical controls to assess treatment…
Read More “Using External and Historical Controls in Phase 2 Trials” »
Protocol Amendment Management in Phase 3 Trials: Impact and Risk Control Strategies Managing Protocol Amendments During Phase 3 Trials: A Practical Guide Understanding Protocol Amendments in Phase 3 Protocol amendments are modifications made to a clinical trial protocol after the trial has started. In Phase 3 trials—where regulatory scrutiny, patient numbers, and operational complexity are…
Read More “Protocol Amendment Management in Phase 3 Trials: Impact and Risk Control Strategies” »
Early Termination of Phase 2 Trials: Criteria and Communication When and How to Terminate a Phase 2 Trial Early: Criteria, Ethics, and Communication Strategies Introduction Early termination of a Phase 2 trial—whether due to futility, safety concerns, or overwhelming efficacy—is a critical decision that can impact patients, sponsors, regulators, and future development plans. While stopping…
Read More “Early Termination of Phase 2 Trials: Criteria and Communication” »
Post-Marketing Commitments and Post-Authorization Safety Studies (PASS) How Phase 4 Commitments and PASS Shape Drug Safety Surveillance Introduction After a medicine enters the market, the need for safety monitoring intensifies—not fades. To ensure ongoing evaluation of benefit-risk balance, regulatory agencies may require pharmaceutical companies to undertake post-marketing commitments (PMCs) and conduct Post-Authorization Safety Studies (PASS)….
Read More “Post-Marketing Commitments and Post-Authorization Safety Studies (PASS)” »
